These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25661298)

  • 1. Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.
    Vidal AC; Howard LE; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
    J Urol; 2015 Jul; 194(1):52-7. PubMed ID: 25661298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Kim JH; Doo SW; Yang WJ; Lee KW; Lee CH; Song YS; Jeon YS; Kim ME; Kwon SS
    Int J Urol; 2014 Oct; 21(10):987-90. PubMed ID: 24825391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
    Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
    BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific Antigen Mass Density--A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution.
    Kryvenko ON; Diaz M; Matoso A; Kates M; Cohen J; Swanson GP; Epstein JI
    Urology; 2016 Apr; 90():141-7. PubMed ID: 26773349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster R; Andriole GL; Groskopf J
    J Urol; 2010 Nov; 184(5):1947-52. PubMed ID: 20850153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
    J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
    Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Moreira DM; Gerber L; Thomas JA; Bañez LL; McKeever MG; Freedland SJ
    Int J Urol; 2012 Aug; 19(8):741-7. PubMed ID: 22487442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
    Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
    BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy.
    Lazzeri M; Briganti A; Scattoni V; Lughezzani G; Larcher A; Gadda GM; Lista G; Cestari A; Buffi N; Bini V; Freschi M; Rigatti P; Montorsi F; Guazzoni G
    J Urol; 2012 Oct; 188(4):1137-43. PubMed ID: 22901578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy.
    Bañez LL; Albisinni S; Freedland SJ; Tubaro A; De Nunzio C
    World J Urol; 2014 Apr; 32(2):323-8. PubMed ID: 22847453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
    Sourbeer KN; Howard LE; Andriole GL; Moreira DM; Castro-Santamaria R; Freedland SJ; Vidal AC
    BJU Int; 2015 May; 115(5):736-43. PubMed ID: 24931061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?
    Tombal B; Andriole GL; de la Taille A; Gontero P; Haese A; Remzi M; Speakman M; Smets L; Stoevelaar H
    Urology; 2013 May; 81(5):998-1004. PubMed ID: 23523291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.
    Fowler JE; Bigler SA; Miles D; Yalkut DA
    J Urol; 2000 Mar; 163(3):813-8. PubMed ID: 10687983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.